Patents Assigned to CONTRAFECT CORPORATION
-
Patent number: 11827693Abstract: The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration. The invention includes methods for treatment or prophylaxis combining intranasal or inhalation administration with intraperitoneal or intravenous administration of antibodies.Type: GrantFiled: March 14, 2014Date of Patent: November 28, 2023Assignee: CONTRAFECT CORPORATIONInventors: Michael Wittekind, Adam Vigil
-
Patent number: 11773140Abstract: The present disclosure is directed to lysin-AMP polypeptide constructs, isolated lysin polypeptides, and pharmaceutical compositions comprising the isolated polypeptides and/or lysin-AMP polypeptide constructs. Methods of using the lysin-AMP polypeptide constructs, isolated lysin polypeptides and pharmaceutical compositions are also herein provided. In addition, isolated polynucleotides encoding the lysin-AMP polypeptide constructs and isolated lysin polypeptides are disclosed herein.Type: GrantFiled: March 29, 2019Date of Patent: October 3, 2023Assignee: CONTRAFECT CORPORATIONInventor: Raymond Schuch
-
Patent number: 11524046Abstract: The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.Type: GrantFiled: April 22, 2019Date of Patent: December 13, 2022Assignee: CONTRAFECT CORPORATIONInventors: Raymond Schuch, Robert C. Nowinski, Michael Wittekind, Babar Khan, Jimmy Rotolo
-
Patent number: 11413334Abstract: The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa. The disclosure further provides compositions and methods of incorporating and utilizing lysin polypeptides of the present disclosure for augmenting the efficacy of antibiotics generally suitable for the treatment of Gram-negative bacterial infection.Type: GrantFiled: July 9, 2020Date of Patent: August 16, 2022Assignee: CONTRAFECT CORPORATIONInventors: Raymond Schuch, Simon Hoffenberg, Michael Wittekind
-
Patent number: 11357833Abstract: The present disclosure relates to methods for restoring or augmenting bactericidal activity of an antibiotic in an organ or tissue in which pulmonary surfactant is present. More specifically, the present disclosure describes that inhibition of antibiotics due to environmental factors, such as the presence of pulmonary surfactant in an organ or tissue such as the respiratory epithelium can be sidestepped or overcome and the effectiveness of the antibiotic in that milieu restored or augmented by co-administration of an antibiotic and a lysin.Type: GrantFiled: September 16, 2016Date of Patent: June 14, 2022Assignee: CONTRAFECT CORPORATIONInventors: Michael Wittekind, Raymond Schuch
-
Patent number: 11246928Abstract: Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that hind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.Type: GrantFiled: November 5, 2019Date of Patent: February 15, 2022Assignees: CONTRAFECT CORPORATION, TRELLIS BIOSCIENCE, LLCInventors: Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
-
Patent number: 10988520Abstract: The present disclosure is directed to a lysin-AMP polypeptide construct comprising: (a) a first component comprising the polypeptide sequence of: (i) SEQ ID NO: 118 (GN202); or (ii) a polypeptide having lysin activity and having at least 80% sequence identity with the polypeptide sequence of SEQ ID NO: 118 (GN202); or (iii) an active fragment of SEQ ID NO: 118 (GN202); and (b) a second component comprising the polypeptide sequence of at least one antimicrobial peptide (AMP), wherein the at least one AMP comprises SEQ ID NO: 114 (FIRL). Exemplary lysin-AMP polypeptides, such as GN370 (SEQ ID NO: 44) as well as methods of treating bacterial infections using the present lysin-AMP polypeptide constructs are also disclosed.Type: GrantFiled: January 30, 2020Date of Patent: April 27, 2021Assignee: CONTRAFECT CORPORATIONInventor: Raymond Schuch
-
Patent number: 10851401Abstract: The present invention provides components, assays and methods for evaluating antibacterial effectiveness and determining minimal inhibitory concentration (MIC) of polypeptides, including lysin polypeptides, that kill bacteria. Modified broth microdilution components and methods are provided, including supplements to enable accurate MIC determination mimicking lysin polypeptide activity in human matrices including serum and blood.Type: GrantFiled: May 12, 2017Date of Patent: December 1, 2020Assignee: CONTRAFECT CORPORATIONInventor: Raymond Schuch
-
Patent number: 10813983Abstract: The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).Type: GrantFiled: May 9, 2013Date of Patent: October 27, 2020Assignee: CONTRAFECT CORPORATIONInventors: Raymond Schuch, Robert C. Nowinski, Michael Wittekind, Han Lee, Brent Schneider
-
Patent number: 10744189Abstract: The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa. The disclosure further provides compositions and methods of incorporating and utilizing lysin polypeptides of the present disclosure for augmenting the efficacy of antibiotics generally suitable for the treatment of Gram-negative bacterial infection.Type: GrantFiled: September 16, 2016Date of Patent: August 18, 2020Assignee: CONTRAFECT CORPORATIONInventors: Raymond Schuch, Simon Hoffenberg, Michael Wittekind
-
Patent number: 10639370Abstract: Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that bind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.Type: GrantFiled: February 4, 2015Date of Patent: May 5, 2020Assignees: CONTRAFECT CORPORATION, TRELLIS BIOSCIENCE, LLCInventors: Angeles Estelles, Lawrence M. Kauvar, Adam Vigil, Michael Wittekind
-
Publication number: 20190106724Abstract: The present invention provides components, assays and methods for evaluating antibacterial effectiveness and determining minimal inhibitory concentration (MIC) of polypeptides, including lysin polypeptides, that kill bacteria. Modified broth microdilution components and methods are provided, including supplements to enable accurate MIC determination mimicking lysin polypeptide activity in human matrices including serum and blood.Type: ApplicationFiled: May 12, 2017Publication date: April 11, 2019Applicant: ContraFect CorporationInventor: Raymond SCHUCH
-
Patent number: 9889181Abstract: The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).Type: GrantFiled: June 4, 2013Date of Patent: February 13, 2018Assignee: CONTRAFECT CORPORATIONInventors: Raymond Schuch, Robert C. Nowinski, Michael Wittekind, Han Lee, Brent Schneider
-
Patent number: 9731010Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of, gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.Type: GrantFiled: March 9, 2015Date of Patent: August 15, 2017Assignees: The Rockefeller University, Contrafect CorporationInventors: Robert C. Nowinski, Vincent A. Fischetti, Assaf Raz
-
Patent number: 9718875Abstract: The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration. The invention includes methods for treatment or prophylaxis combining intranasal or inhalation administration with intraperitoneal or intravenous administration of antibodies.Type: GrantFiled: September 16, 2016Date of Patent: August 1, 2017Assignee: ContraFect CorporationInventors: Michael Wittekind, Adam Vigil
-
Patent number: 9499594Abstract: The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphlococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.Type: GrantFiled: May 9, 2013Date of Patent: November 22, 2016Assignee: Contrafect CorporationInventors: Raymond Schuch, Robert C. Nowinski, Michael Wittekind, Babar Khan, Jimmy Rotolo
-
Publication number: 20150290299Abstract: The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).Type: ApplicationFiled: May 9, 2013Publication date: October 15, 2015Applicant: Contrafect CorporationInventors: Raymond Schuch, Robert C. Nowinski, Michael Wittekind, Han Lee, Brent Schneider
-
Patent number: 9005579Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.Type: GrantFiled: January 5, 2011Date of Patent: April 14, 2015Assignees: Contrafect Corporation, The Rockfeller UniversityInventors: Robert C. Nowinski, Vincent A. Fischetti, Assaf Raz
-
Publication number: 20130045211Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.Type: ApplicationFiled: January 5, 2011Publication date: February 21, 2013Applicants: THE ROCKEFELLER UNIVERSITY, CONTRAFECT CORPORATIONInventors: Robert C. Nowinski, Vincent A. Fischetti, Assaf Raz